Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
UNKNOWN
Development Phase
Unknown
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Leucine (this asset) | Washington University School of Medicine | Unk | D · 30 |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| Donanemab | Eli Lilly and Company | P3 | BB |
| Encenicline | FORUM Pharmaceuticals Inc | P2 | BB |
| 2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE | Taichung Veterans General Hospital | P4 | B |
| Levodopa | Merck Sharp & Dohme LLC | P2 | B |
| Dexasone | Eli Lilly and Company | P3 | B |
+42 more in the Central Nervous System Disorder cohort
Other indications for L-Leucine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P2 | CCC · 53 |
| Brain Disorder | — | Unk | D · 30 |
| Alzheimer Disease | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Leucine in Central Nervous System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-leucine-central-nervous-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →